OGN News and Press, Organon & Co. From 05/05/22

First quarter 2022 revenue of $1,567 million Net income from continuing operations of $348 million, or $1.36 per diluted share; Adjusted net income from continuing operations of $420 million, or $1.65 per diluted share Adjusted EBITDA of $647 million Board of Directors dec...

Organon (NYSE:OGN) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is $1.30 and the consensus Revenue Estimate is $1.52B (+0.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue es...

Goldman Sachs boosted its forecast for dividend growth this year, with earnings growth the primary driver. The equity team now sees dividend growth of +10% for 2022. S&P 500 (SP500) (SPY) dividends per shares "grew by +11% year/year in 1Q 2022," strategist David Kostin wrote in a note. "I...

Kahn Brothers’ 13F portfolio value increased from $741M to $788M this quarter. Citigroup, ViewRay, and VOXX International were increased during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 13F holdings. ...

Biosimilar sales were $118 million in Q4 2021, up 14.6% from Q4 2020. Organon's dividend yield is around 3.5%, which is one of the largest in the pharmaceutical industry. In July 2023, the company expects to start selling the biosimilar Humira, whose patented drug brought AbbVie a...

Goldman Sachs has launched its coverage on Organon (NYSE:OGN), arguing, among other things, that the market hasn’t adequately appreciated the Women's Health (WH) business of the Merck (MRK) spinoff. The price target set to $40 per share implies a premium of ~26% to the last close. The ...

The European Union drug regulator's Committee for Medicinal Products for Human Use recommended extending the indication for Organon's (NYSE:OGN) fertility treatment, Elonva.  The drug regulator said Elonva is indicated for the treatment of adolescent males, that are 14 years and older, w...

Organon (NYSE: OGN), will release its first quarter 2022 financial results on May 5, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. Interested parties may access the live call via webcast on the Organon website at https://www.organon.c...

Pharmaceuticals and biotechnology still are attractive regarding value and quality. Other subsectors are overvalued by 15% to 42% relative to 11-year averages. Fast facts on IBB. 10 healthcare stocks cheaper than their peers in April. For further details see: IBB: He...

Fundamental Diagnosis is an individual investor and former sell-side analyst in healthcare at several top investment banks. The risks of relying too much on the narrative for a stock, how a competitive analysis can serve as a source of idea gen and using a company’s investor pr...